Won Soon Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Won Soon Park has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Yun Sil Chang
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
16 shared publicationsJ Y Lee
9 shared publicationsM S Shin
Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 137-701, Korea
9 shared publicationsN J Yoo
9 shared publicationsS H Lee
9 shared publicationsS Y Kim
9 shared publications
Latest Publications
- 24 November 2016
- Published by Georg Thieme Verlag KG in Neonatologie Scan
- Vol. 05 (04) , 266-267
Neonatale Hirnschäden: präklinische Forschung zur Stammzelltherapie
Auch wenn noch viele Detailfragen zu erforschen sind, was in longitudinalen Tierstudien erfolgen sollte, haben die präklinischen Ergebnisse nach Ansicht der Autoren die humane Stammzelltherapie für neonatale Hirnschäden dem klinischen Einsatz einen Schritt näher gebracht. Eine klinische Phase-I-Studie an Frühgeborenen mit schwerer IVH mit steigenden Dosen humaner Nabelschnurblut-MSC wurde bereits begonnen.
- 24 November 2016
- Published by Georg Thieme Verlag KG in Neonatologie Scan
- Vol. 05 (04) , 266-267
Neonatale Hirnschäden: präklinische Forschung zur Stammzelltherapie
Auch wenn noch viele Detailfragen zu erforschen sind, was in longitudinalen Tierstudien erfolgen sollte, haben die präklinischen Ergebnisse nach Ansicht der Autoren die humane Stammzelltherapie für neonatale Hirnschäden dem klinischen Einsatz einen Schritt näher gebracht. Eine klinische Phase-I-Studie an Frühgeborenen mit schwerer IVH mit steigenden Dosen humaner Nabelschnurblut-MSC wurde bereits begonnen.
- 1 June 2012
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 16, e306
Immunogenicity of single-dose hepatitis A vaccines in young adults
- 1 June 2012
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 16, e306
Immunogenicity of single-dose hepatitis A vaccines in young adults
- Open Access
- 1 January 2009
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 52 (12) , 1392-1395
A case of pulmonary vascular air embolism in a very-low-birth-weight infant with massive hydrops
Kim MJ, et al. Korean J Pediatr. 2009 Dec;52(12):1392-1395. http://dx.doi.org/10.3345/kjp.2009.52.12.1392
- 1 January 2009
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 52 (12) , 1392-1395
Open AccessA case of pulmonary vascular air embolism in a very-low-birth-weight infant with massive hydrops
Kim MJ, et al. Korean J Pediatr. 2009 Dec;52(12):1392-1395. http://dx.doi.org/10.3345/kjp.2009.52.12.1392
- Open Access
- 1 January 2008
- Published by XMLink in Yonsei Medical Journal
- Vol. 49 (1) , 144-150
Intratracheal Administration of Endotoxin Attenuates Hyperoxia-Induced Lung Injury in Neonatal Rats
Shim JW, et al. Yonsei Med J. 2008 Feb;49(1):144-150. https://doi.org/10.3349/ymj.2008.49.1.144
- 1 January 2008
- Published by XMLink in Yonsei Medical Journal
- Vol. 49 (1) , 144-150
Open AccessIntratracheal Administration of Endotoxin Attenuates Hyperoxia-Induced Lung Injury in Neonatal Rats
Shim JW, et al. Yonsei Med J. 2008 Feb;49(1):144-150. https://doi.org/10.3349/ymj.2008.49.1.144
- Open Access
- 1 January 2007
- Published by XMLink in Yonsei Medical Journal
- Vol. 48 (4) , 619-626
A Comparison of AmBisome® to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants
Jeon GW, et al. Yonsei Med J. 2007 Aug;48(4):619-626. http://dx.doi.org/10.3349/ymj.2007.48.4.619
- 1 January 2007
- Published by XMLink in Yonsei Medical Journal
- Vol. 48 (4) , 619-626
Open AccessA Comparison of AmBisome® to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants
Jeon GW, et al. Yonsei Med J. 2007 Aug;48(4):619-626. http://dx.doi.org/10.3349/ymj.2007.48.4.619
- Open Access
- 1 January 2007
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 50 (11) , 1067-1071
Improved survival rate with decreased neurodevelopmental disability in extreme immaturity
Jeon GW, et al. Korean J Pediatr. 2007 Nov;50(11):1067-1071. http://dx.doi.org/10.3345/kjp.2007.50.11.1067
- 1 January 2007
- Published by Korean Pediatric Society in Korean Journal of Pediatrics
- Vol. 50 (11) , 1067-1071
Open AccessImproved survival rate with decreased neurodevelopmental disability in extreme immaturity
Jeon GW, et al. Korean J Pediatr. 2007 Nov;50(11):1067-1071. http://dx.doi.org/10.3345/kjp.2007.50.11.1067
- Open Access
- 1 January 2007
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 22 (6) , 1042-1047
Erythropoietin Attenuates Hyperoxia-Induced Lung Injury by Down-modulating Inflammation in Neonatal Rats
Lee JH, et al. J Korean Med Sci. 2007 Dec;22(6):1042-1047. http://dx.doi.org/10.3346/jkms.2007.22.6.1042
- 1 January 2007
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 22 (6) , 1042-1047
Open AccessErythropoietin Attenuates Hyperoxia-Induced Lung Injury by Down-modulating Inflammation in Neonatal Rats
Lee JH, et al. J Korean Med Sci. 2007 Dec;22(6):1042-1047. http://dx.doi.org/10.3346/jkms.2007.22.6.1042
- Open Access
- 1 January 2007
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 22 (6) , 1042-1047
Erythropoietin Attenuates Hyperoxia-Induced Lung Injury by Down-modulating Inflammation in Neonatal Rats
Lee JH, et al. J Korean Med Sci. 2007 Dec;22(6):1042-1047. http://dx.doi.org/10.3346/jkms.2007.22.6.1042
- 1 January 2007
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 22 (6) , 1042-1047
Open AccessErythropoietin Attenuates Hyperoxia-Induced Lung Injury by Down-modulating Inflammation in Neonatal Rats
Lee JH, et al. J Korean Med Sci. 2007 Dec;22(6):1042-1047. http://dx.doi.org/10.3346/jkms.2007.22.6.1042
- Open Access
- 1 January 2006
- Published by XMLink in Journal of Korean Medical Science
- Vol. 21 (6) , 965-972
Pretreatment with N-nitro-L-arginine Methyl Ester Improved Oxygenation After Inhalation of Nitric Oxide in Newborn Piglets with Escherichia coli Pneumonia and Sepsis
Chang YS, et al. J Korean Med Sci. 2006 Dec;21(6):965-972. http://dx.doi.org/10.3346/jkms.2006.21.6.965
- 1 January 2006
- Published by XMLink in Journal of Korean Medical Science
- Vol. 21 (6) , 965-972
Open AccessPretreatment with N-nitro-L-arginine Methyl Ester Improved Oxygenation After Inhalation of Nitric Oxide in Newborn Piglets with Escherichia coli Pneumonia and Sepsis
Chang YS, et al. J Korean Med Sci. 2006 Dec;21(6):965-972. http://dx.doi.org/10.3346/jkms.2006.21.6.965
- Open Access
- 1 January 2005
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 20 (4) , 591-597
Comparison of Clinical Efficacy of Newfactan® versus Surfacten® for the Treatment of Respiratory Distress Syndrome in the Newborn Infants
Newfactan® is a domestically developed, bovine lung-derived, semi-synthetic surfactant. The aim of this study was to compare the clinical efficacy of Newfactan® with that of Surfacten® in the treatment of respiratory distress syndrome (RDS). Newfactan® or Surfacten® was randomly allocated to 492 newborn infants who were diagnosed as RDS and required surfactant instillation in four participating hospitals. The comparisons were made individually in two subsets of infants by birth weight (<1,500 g group [n=253] and ≥1,500 g group [n=239]). Short-term responses to surfactant and acute complications, such as the total doses of surfactant instilled, response type, extubation rate, ventilator settings, changes in respiratory parameters, air leak, patent ductus arteriosus, pulmonary hemorrhage, and intraventricular hemorrhage, and mortality during the 96 hr after surfactant instillation were measured. Long-term outcome and complications, such as total duration of intubation, bronchopulmonary dysplasia and periventricular leukomalacia, and ultimate mortality were measured. There were no significant differences in demographic and perinatal variables, short-term responses to surfactant and acute complications, and long-term outcome and complications between Newfactan® and Surfacten® in both birth weight groups. We concluded that Newfactan® was comparable to Surfacten® in the clinical efficacy in the treatment of RDS in both birth weight groups.
- 1 January 2005
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 20 (4) , 591-597
Open AccessComparison of Clinical Efficacy of Newfactan® versus Surfacten® for the Treatment of Respiratory Distress Syndrome in the Newborn Infants
Newfactan® is a domestically developed, bovine lung-derived, semi-synthetic surfactant. The aim of this study was to compare the clinical efficacy of Newfactan® with that of Surfacten® in the treatment of respiratory distress syndrome (RDS). Newfactan® or Surfacten® was randomly allocated to 492 newborn infants who were diagnosed as RDS and required surfactant instillation in four participating hospitals. The comparisons were made individually in two subsets of infants by birth weight (<1,500 g group [n=253] and ≥1,500 g group [n=239]). Short-term responses to surfactant and acute complications, such as the total doses of surfactant instilled, response type, extubation rate, ventilator settings, changes in respiratory parameters, air leak, patent ductus arteriosus, pulmonary hemorrhage, and intraventricular hemorrhage, and mortality during the 96 hr after surfactant instillation were measured. Long-term outcome and complications, such as total duration of intubation, bronchopulmonary dysplasia and periventricular leukomalacia, and ultimate mortality were measured. There were no significant differences in demographic and perinatal variables, short-term responses to surfactant and acute complications, and long-term outcome and complications between Newfactan® and Surfacten® in both birth weight groups. We concluded that Newfactan® was comparable to Surfacten® in the clinical efficacy in the treatment of RDS in both birth weight groups.